Faes Farma : Transformational M&A reshapes Faes’ strategic profile
The acquisitions of Edol and SIFI mark a turning point. With € 345m investment combined, Faes consolidates its position in ophthalmology. Both complement its pharma portfolio and provide access to manufacturing, regulatory and R&D capabilities in high-growth segments. The combined footprint supports its ambition to reach € 1bn in sales by 2030, while diversifying beyond Iberia. We raise our TP by € 1.2 to € 6 mostly on SIFI and reiterate our positive view.Faes Farma is engaged in the health care research, manufacture and sale of prescription pharmaceuticals, over-the-counter pharmaceuticals and fine chemicals, URGO bandages and dressings and LAZLO cosmetics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.